A cell-permeable inhibitor for the E1 enzyme UBA1 is developed and used in clinical trials, but given the pleiotropic behavior of E1 enzymes, these inhibitors could only be used in acute settings such as aggressive cancers (Hyer et al., 2018). Here, UBA1 is linked to cancer.